470 related articles for article (PubMed ID: 22365299)
41. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
42. Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon.
Pati S; Das MK; Rana A; Das E; Sarkar S; Sherpa N; Datta S
Indian J Pediatr; 2021 Nov; 88(11):1142-1144. PubMed ID: 34106442
[TBL] [Abstract][Full Text] [Related]
43. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
44. Bullous Kaposiform Hemangioendothelioma Masquerading as Aplasia Cutis Congenita.
Steen AJ; Shin JH; Pace NC; Edgar M; Clay MR; Linos K; Barton DT; Mann JA
Pediatr Dermatol; 2016 Sep; 33(5):e267-9. PubMed ID: 27339319
[TBL] [Abstract][Full Text] [Related]
45. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
46. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
47. Kaposiform hemangioendothelioma arising in the deltoid muscle without the Kasabach-Merritt phenomenon.
Tamai N; Hashii Y; Osuga K; Chihara T; Morii E; Aozasa K; Yoshikawa H
Skeletal Radiol; 2010 Oct; 39(10):1043-6. PubMed ID: 20309545
[TBL] [Abstract][Full Text] [Related]
48. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Chiu YE; Drolet BA; Blei F; Carcao M; Fangusaro J; Kelly ME; Krol A; Lofgren S; Mancini AJ; Metry DW; Recht M; Silverman RA; Tom WL; Pope E
Pediatr Blood Cancer; 2012 Nov; 59(5):934-8. PubMed ID: 22648868
[TBL] [Abstract][Full Text] [Related]
49. Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery.
Jiang RS; Hu R
Int J Clin Oncol; 2012 Oct; 17(5):512-6. PubMed ID: 21947597
[TBL] [Abstract][Full Text] [Related]
50. Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D.
Hu B; Lachman R; Phillips J; Peng SK; Sieger L
J Pediatr Hematol Oncol; 1998; 20(6):567-9. PubMed ID: 9856681
[TBL] [Abstract][Full Text] [Related]
51. Successful management of a retroperitoneal kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using alpha-interferon.
Harper L; Michel JL; Enjolras O; Raynaud-Mounet N; Rivière JP; Heigele T; De Napoli-Cocci S
Eur J Pediatr Surg; 2006 Oct; 16(5):369-72. PubMed ID: 17160787
[TBL] [Abstract][Full Text] [Related]
52. Kaposiform Haemangioendothelioma-spectrum Lesions with Kasabach-Merritt Phenomenon: Retrospective Analysis and Long-term Outcome.
Boccara O; Fraitag S; Lasne D; Fontaine J; Bughin V; Hamel-Teillac D; Orbach D; Brunelle F; de Prost Y; Hadj-Rabia S; Bodemer C
Acta Derm Venereol; 2016 Jan; 96(1):77-81. PubMed ID: 26084625
[TBL] [Abstract][Full Text] [Related]
53. Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon: a retrospective cohort study.
Zhang G; Chen H; Gao Y; Liu Y; Wang J; Liu XY
Br J Dermatol; 2018 May; 178(5):1213-1214. PubMed ID: 29388191
[No Abstract] [Full Text] [Related]
54. Management of Refractory Pediatric Kaposiform Hemangioendothelioma With Sirolimus and Aspirin.
MacFarland SP; Sullivan LM; States LJ; Bailey LC; Balamuth NJ; Womer RB; Olson TS
J Pediatr Hematol Oncol; 2018 May; 40(4):e239-e242. PubMed ID: 29240034
[TBL] [Abstract][Full Text] [Related]
55. Bone kaposiform hemangioendothelioma: A rare entity dramatically improved by sirolimus.
Boccara O; Dangien A; Fitoussi F; Ducou Le Pointe H; Coulomb L'Hermine A; Fraitag S; Lorrot M
J Paediatr Child Health; 2022 Sep; 58(9):1676-1679. PubMed ID: 35138010
[No Abstract] [Full Text] [Related]
56. Interferon-alpha therapy for refractory kaposiform hemangioendothelioma: a single-center experience.
Wu HW; Wang X; Zhang L; Zhao HG; Wang YA; Su LX; Fan XD; Zheng JW
Sci Rep; 2016 Oct; 6():36261. PubMed ID: 27796340
[TBL] [Abstract][Full Text] [Related]
57.
Russell TB; Rinker EK; Dillingham CS; Givner LB; McLean TW
Pediatrics; 2018 Apr; 141(Suppl 5):S421-S424. PubMed ID: 29610164
[TBL] [Abstract][Full Text] [Related]
58. Intra-abdominal Kaposiform hemangioendothelioma and the benefits of laparoscopic surveillance.
Thompson CV; Wells JM; Bowen C; Brundler MA; Kearns P; Arul GS
Pediatr Blood Cancer; 2012 Jun; 58(6):992-3. PubMed ID: 22431247
[TBL] [Abstract][Full Text] [Related]
59. First Intracardiac Kaposiform Hemangioendothelioma in an Infant Resolved With Sirolimus: A Case Report.
Zaidi SJ; Shaik S; Agrawal C; Cossor W
J Pediatr Hematol Oncol; 2018 Oct; 40(7):536-540. PubMed ID: 30067556
[TBL] [Abstract][Full Text] [Related]
60. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon.
Gruman A; Liang MG; Mulliken JB; Fishman SJ; Burrows PE; Kozakewich HP; Blei F; Frieden IJ
J Am Acad Dermatol; 2005 Apr; 52(4):616-22. PubMed ID: 15793511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
